Description: Medifron DBT Co., Ltd., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. The company was formerly known as Legend Technologies Inc. and changed its name to Medifron DBT Co., Ltd. in 2006. Medifron DBT Co., Ltd. was incorporated in 1997 and is based in Seoul, South Korea.
Home Page: www.medifron.com
186, Gasan digital 1-ro
Seoul,
08502
South Korea
Phone:
82 2 545 9277
Officers
| Name | Title |
|---|---|
| Mr. Hyun-Sang Muk | Chief Exec. Officer and Representative Director |
| Mr. Young-Ho Kim | Chief Exec. Officer and Representative Director |
| Mr. Dong-Bum Im | Head of Information Technology Department and Director |
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 1.326 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 33 |